ArticlePsychopharmacology2021
A potential probiotic bacterium for antipsychotic-induced metabolic syndrome: mechanisms underpinning how Akkermansia muciniphila subtype improves olanzapine-induced glucose homeostasis in mice.
Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Unravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review.Dialogues in clinical neuroscience · 2026Pooled it
- Probiotics Supplementation for Improving Glucolipid Parameters in Individuals with Prediabetes: A Systematic Review and Meta-Analysis of Randomized Trials.Probiotics and antimicrobial proteins · 2025Pooled it
- The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis.European archives of psychiatry and clinical neuroscience · 2025Pooled it
- The Role of Probiotics in Managing Glucose Homeostasis in Adults with Prediabetes: A Systematic Review and Meta-Analysis.Journal of diabetes research · 2024Pooled it
- Akkermansia muciniphila Alleviates Olanzapine-Induced Hepatic Steatosis via the Gut Microbiota-IGFBP2/APOA1-Liver Axis.Microbial biotechnology · 2025Article
- Article
- Lack of genotoxicity and subchronic toxicity in safety assessment studies ofToxicology reports · 2024Article
- Altered gut microbiota and systemic immunity in Chinese patients with schizophrenia comorbid with metabolic syndrome.Journal of translational medicine · 2024Article
- A Possible Role of Akkermansia muciniphila in the Treatment of Olanzapine-Induced Weight Gain.Cureus · 2024Review
- Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain.Microbiology spectrum · 2023Article
- When the microbiome helps the brain-current evidence.CNS neuroscience & therapeutics · 2023Review
- Emerging epigenetic dynamics in gut-microglia brain axis: experimental and clinical implications for accelerated brain aging in schizophrenia.Frontiers in cellular neuroscience · 2023Review
- The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications.Frontiers in pharmacology · 2023Review
- Probiotic Mechanisms Affecting Glucose Homeostasis: A Scoping Review.Life (Basel, Switzerland) · 2022Article
- Olanzapine-induced lipid disturbances: A potential mechanism through the gut microbiota-brain axis.Frontiers in pharmacology · 2022Article
- Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines.Frontiers in neuroscience · 2022Review
- Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review.Therapeutic advances in psychopharmacology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOlanzapine (OLZ) is one of the most effective atypical antipsychotics but is associated with severe metabolic side effects, in which the gut microbiota plays an important role. Akkermansia muciniphila (A. muciniphila; Akk), a Gram-negative anaerobic bacterium in the intestine, can potentially improve metabolic syndrome.
objectiveThis study investigated the effect and underlying mechanisms of an A. muciniphila subtype (A. muciniphila
methodsC57BL/6 female mice were fed a high-fat diet to induce obesity or normal chow for 8 weeks before OLZ treatment for 16 weeks. During the treatment period, mice in each group were orally administrated A. muciniphila
resultsA. muciniphila
conclusionsA. muciniphila
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.